.jpg "Karyopharm Therapeutics (NASDAQ: KPTI)")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) and Bluebird Bio (NASDAQ: BLUE) with bullish sentiments.
Karyopharm Therapeutics (NASDAQ: KPTI)
H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $30. The company’s shares opened today at $18.05.
White wrote:
“We believe this data bodes well for the ongoing Phase 3 BOSTON trial, for which top-line data is expected in 2019. We note that standard Vd regimens (control arm of BOSTON) have an ORR of 60-65% and PFS of 7-9 months according to previous studies. More positive data in the selinexor in the STOMP SDd arm. In the combination selinexor, Darzalex, and low dose dex (SDd) arm evaluating MM patients who received at least three prior lines of therapy, including a PI and an immunomodulatory drug (IMiD), or patients with MM refractory to both a PI and an IMiD, the ORR was 74% (n=19) with an ORR of 82% in Darzalex naïve patients (n=17) in evaluable patients as of June 5, 2018. This is relatively in line with prior data, as of for eight Darzalex naïve patients, with an ORR of 88%.”
According to TipRanks.com, White is a 5-star analyst with an average return of 26.7% and a 54.7% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Synthetic Biologics Inc, and Mirati Therapeutics.
Karyopharm Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $24.40.
See today’s analyst top recommended stocks >>
Bluebird Bio (NASDAQ: BLUE)
In a report released today, Raju Prasad from William Blair maintained a Buy rating on Bluebird Bio (NASDAQ: BLUE). The company’s shares opened today at $196.20.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of 32.4% and a 72.7% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Audentes Therapeutics, and Spark Therapeutics.
Currently, the analyst consensus on Bluebird Bio is Moderate Buy and the average price target is $213, representing an 8.6% upside.
In a report issued on June 4, Cowen & Co. also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
